CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 105 enrolled
Drug / intervention
XmAb5871 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02725515
NCT02725515Phase 2Completed
CompareCT.gov

A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb®5871 on Systemic Lupus Erythematosus Disease Activity

Xencor, Inc.·interventional·Posted Apr 1, 2016·Updated Aug 20, 2019

In Brief

A Phase 2 clinical trial evaluating XmAb5871 and Placebo to match XmAb5871 for Systemic Lupus Erythematosus. Completed, enrolled 105 participants across 23 sites.

Detailed Summary

The purpose of this study is to determine the ability of XmAb5871 to maintain Systemic Lupus Erythematosus (SLE) disease activity improvement achieved by a brief course of disease-suppressing steroid therapy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesUnited States
CollaboratorsPPD Development, LP, ICON plc

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 1, 2016
Enrollment StartFeb 16, 2016
Primary CompletionJul 17, 2018
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.3 years ago

Interventions

XmAb5871biological

Placebo to match XmAb5871biological